According to the World Cancer Report, cancer rates will continue to rise to 15 million new cases by 2020. Global biopsy device market will be USD 2.8 Billion by 2025.
"Cancer is the second-leading cause of death and disability in the world, behind only heart disease. More people die from cancer every year around the world than AIDS, Tuberculosis and Malaria combined. Cancer testing has tremendous growth opportunities for the next five years. According to the National Cancer Institute (NCI), 85% of cancer patients are treated in community-based, private practice oncology settings.
Prostate Cancer Testing market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Prostate Cancer Testing market will be able to gain the upper hand as they use the report as a powerful resource.
Cancer Testing Screening Market size is projected to reach $220.66 billion by 2027 and is expected to grow at a CAGR of 6.4% during the forecast period 2022-2027. Cancer Testing and Screening are vital procedures for aid in the early detection of cancer before symptoms occur.
iGATE RESEARCH report titled “Global Prostate Cancer Therapeutics Market to 2020” is a 76 page report with 43 Figures and 4 Tables. This report analyses the Prostate Cancer Therapy Market, Prostate Cancer Drugs Market, driving factors and challenges for prostate cancer market. Click here to view the complete report: http://www.igateresearch.com/ProductDetail.php?pd_name=Global%20Prostate%20Cancer%20Therapeutics%20Market%20to%202020 Contact US iGATE Research PVT LTD Ravi Sinha Sales Manager Marketing and Sales Divison Email: ravi.sinha@igateresearch.com Contact: +91-858-684-0791, +91-706-527-9335 (INDIA) Web: www.igateresearch.com
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026.
The Prostate Cancer Diagnostics Market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022.
The global prostate cancer testing market was valued at $5,246.9 million in 2021, and it is expected to reach $21,306.9 million by 2032, growing at a CAGR of 13.68% during the forecast period 2022-2032.
Prostate Cancer Pipeline Review, 2015 provides an overview of Prostate Cancer diagnostic tests currently in pipeline stage. Enquiry about report: http://www.researchbeam.com/prostate-cancer-pipeline-review-2015-market/enquire-about-report
The Report on “Cancer Diagnostic Tests Market Size, Share, Growth, Profit, Analysis, Trends and Strategy 2016" added by Research Beam Enquiry about report: http://www.researchbeam.com/2016-emerging-cancer-diagnostic-tests-and-strategic-profile-of-leading-reagent-and-instrument-suppliers-market/enquire-about-report
Download Sample Brochure@ http://tinyurl.com/j3jt7ly Marketintelreports, ‘Prostate Cancer - Pipeline Review, H2 2015’, provides an overview of the Prostate Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects.
Get a new survey on "2015 Prostatic Acid Phosphatase Testing Technologies and Emerging Market" provided by Big Market Research Read The Full Report On : http://www.bigmarketresearch.com/2015-prostatic-acid-phosphatase-testing-technologies-and-emerging-market This report contains 242 pages, 11 tables and presents a detailed analysis of the PAP testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.
As per report analysis China Cancer Test Market is projected to cross US$ 24 Billion by the end of 2022. In China, cancer cases are rising and are one of the major causes of deaths in urban and rural areas.
This new report from Venture Planning Group contains 521 pages, 41 tables, and presents a comprehensive analysis of the Spanish hospital tumor marker testing market, including: Major issues pertaining to the Spanish hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Test volume and sales forecasts for 40 tumor markers performed in Spanish hospitals. Current instrumentation technologies and feature comparison of leading analyzers. Complete report available @ http://www.reportsnreports.com/reports/274120-spanish-hospital-tumor-marker-testing-market-2014.html
Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages.
Europe has a larger share of the Prostate Specific Antigen (PSA) Market. It is expected to reach $1238.8 Million by 2023 with a CAGR of 3.37% in the coming years.
The key objective is to present a comprehensive analysis of the current state of prostate cancer therapy and technology, utilization of the various therapeutic and diagnostic modalities to prevent and treat prostate cancer. The report’s focus is on prostate cancer treatment strategies such as hormone therapy, chemotherapy, radiotherapy and immunotherapy, and other treatment modalities and testing and screening methods.
Access full Research: https://www.renub.com/point-of-care-testing-market-and-forecast-to-2016-global-analysis-158-p.php Point of Care Testing Market is anticipated to be US$ 36 Billion, by 2024 experiencing a significant growth over the forecast period. The concept of Point of Care Testing (POCT), also known as bedside, near-patient testing and decentralized testing, relates to tests that are conducted by clinical operators at the site of patient care where immediate medical action is taken on the results. The fact that point of care (POCT) represents a departure from conventional laboratory medicine has created new opportunities in the field of diagnostics industry.
Bharat Book Bureau present's a new report on "2014 Opportunities in the US Hospital Tumor Marker Testing Market" which presents a comprehensive analysis of the US hospital tumor market testing market.
3nd African American Prostate Cancer Disparity Summit Prostate Health Education Network (PHEN) V. Diane Woods, Dr.P.H., M.S.N., R.N. Assistant Research Psychologist ...
The report entitled “Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020)”, provides. For details, write to info@daedal-research.com
Metastatic Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Prostate Cancer. Browse full report @ http://bit.ly/1wdcwzs
Prostate Specific Antigen is secreted by epithelial prostatic cells. The PSA is present in serum which is used to detect prostate cancer. There is a continuous circulation of PSA in the blood. There is high demand for the Prostate Specific Antigen (PSA) Testing Market due to the rising cases of prostate cancer across the globe during 2015-2020.
Big Market Research has announced a new Report Package "UK Tumor Marker Testing Market- Types, End Users, Size, Share, Trends, Forecast, Development, Situation, Future outlook, Potential" Get Complete Details At: http://www.bigmarketresearch.com/2015-2019-uk-tumor-marker-testingus-europe-japan-emergingopportunities-and-growth-strategiesfor-instrument-and-reagent-suppliers-market Highlights Comprehensive 575-page analysis of the UK tumor marker testing market. Major issues pertaining to the UK laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Enquire About This Report at: http://www.bigmarketresearch.com/report-enquiry/302626
Big Market Research has announced a new Report Package "US Tumor Marker Testing Market - Types, End Users, Size, Share, Trends, Forecast, Development, Situation, Future outlook, Potential" Get Complete Details At: http://www.bigmarketresearch.com/2015-2019-us-tumor-marker-testingus-europe-japan-emergingopportunities-and-growth-strategiesfor-instrument-and-reagent-suppliers-market Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Enquire About This Report at: http://www.bigmarketresearch.com/report-enquiry/302627
Get exclusive report on "2015 World Cancer Diagnostics Market: Emerging Tests, Technology Assessment, Instrumentation Review, Sales Forecasts by Country and Strategic Profiles of Leading Suppliers" By Big Market Research Read The Complete Report On : http://www.bigmarketresearch.com/2015-world-cancer-diagnostics-emerging-tests-technology-assessment-instrumentation-review-sales-forecasts-by-country-and-strategic-profiles-of-leading-suppliers-market This new report provides analysis of the global cancer diagnostics market, including emerging tests, technologies, instrumentation, sales forecasts by country, and strategic profiles of leading suppliers.
Global Cancer Diagnostics market size was $18.31 Billion in 2022 and it is forecasted to reach $36.72 Billion by 2030. Cancer Diagnostics Industry's Compound Annual Growth Rate will be 10.3% from 2023 to 2030.
Access full Research: http://www.renub.com/china-cancer-test-market-volume-forecast-male-female-p.php As per Renub Research analysis China Cancer Test Market is projected to cross US$ 24 Billion by the end of 2022. In China, cancer cases are rising and are one of the major causes of deaths in urban and rural areas. In order to mitigate cancer prevalence in China; the government focuses on several Cancer Control Programs which include prevention, early diagnosis and treatment. Early diagnosis programs include screening for breast and cervix cancer while prevention programs such as anti-smoking campaigns and immunization against hepatitis. Public awareness against cancer and the promotion of healthy lifestyle have also been carried out actively. Growing Lung Cancer out of 26 Cancer Cases Studied in the Report Cancer is one of the most significant public health burdens in China. China has exceptional number of lung cancer diagnoses and deaths than any other part of the world.
Renub Research has announced the addition of the "http://www.renub.com/global-prostate-cancer-therapeutics-market-to-2020-487-p.php" report to its offering
Market Overview: Cancer Tissue Diagnostics Market Cancer tissue diagnostics play a pivotal role in oncology by facilitating accurate diagnosis, prognosis, and treatment selection based on tissue samples obtained from patients. The global cancer tissue diagnostics market is witnessing steady growth, driven by the increasing incidence of cancer, advancements in diagnostic technologies, and growing emphasis on personalized medicine.
This unique report from provides information and analysis not available from any other published source, including 2022 supplier strategies and shares, and 2022-2027 volume and sales forecasts for major tumor markers. The report also provides a comprehensive lists of companies developing or marketing new technologies and products by test.
This unique report from provides information and analysis not available from any other published source, including 2022 supplier strategies and shares, and 2022-2027 volume and sales forecasts for major tumor markers
Global Cancer Diagnostics Market is expected to rise from its initial estimated value of USD 143.89 billion in 2018 to a projected value of USD 244.28 billion by 2026
Global Cancer Diagnostics Market is expected to rise from its initial estimated value of USD 143.89 billion in 2018 to a projected value of USD 244.28 billion by 2026
The report also provides a comprehensive lists of companies developing or marketing new technologies and products by test.The report is available by section, and can be customized to specific information needs and budget.
Global Cancer Diagnostics Market is expected to rise from its initial estimated value of USD 143.89 billion in 2018 to a projected value of USD 244.28 billion by 2026
Global Cancer Diagnostics Market is expected to rise from its initial estimated value of USD 143.89 billion in 2018 to a projected value of USD 244.28 billion by 2026
Global Cancer Diagnostics Market is expected to rise from its initial estimated value of USD 143.89 billion in 2018 to a projected value of USD 244.28 billion by 2026
Global Cancer Diagnostics Market is expected to rise from its initial estimated value of USD 143.89 billion in 2018 to a projected value of USD 244.28 billion by 2026, registering a CAGR of 6.84% in the forecast period of 2019-2026.
The Global Tumor Biomarker Test Market witnessed a rapid growth in the historic period from 2016 to 2019 and is anticipated to witness significant growth during the forecast period.
Global solid tumor testing market size is expected at $33.91 Bn by 2027 at a growth rate of 7.1% and share analysis outlook by The Business Research Company.
The global market for prostate cancer products reached nearly $47.2 billion in 2016 and should reach nearly $65.1 billion in 2021, with a compound annual growth rate (CAGR) of 6.6%. Report Scope: The scope of this study is testing, screening technology and also therapeutics markets for prostate cancer. The report also includes the regulatory environment, current technologies, new technologies, prostate cancer incidence, market projections and market share, along with latest trends and new developments. Get More Information sample: https://www.trendsmarketresearch.com/report/sample/11795
The Global Solid Tumor Testing Market size is projected to grow at a CAGR of around 8.0% during the forecast period, 2023-28. In recent years, genomic analysis has impacted the diagnosis, prognostication, monitoring, and treatment decision-making for different solid tumors.
The global cancer diagnostics market size was USD 175.1 billion in 2021 and is projected to grow at a CAGR of 7.2% to reach USD 305.3 billion by 2030. The Cancer Diagnostics Market is a rapidly evolving sector at the forefront of the global healthcare industry. Advancements in technology and increasing cancer prevalence drive market growth. Diagnostic methods like imaging, genomics
Global Cancer Diagnostics Market is expected to rise from its initial estimated value of USD 143.89 billion in 2018 to a projected value of USD 244.28 billion by 2026, registering a CAGR of 6.84% in the forecast period of 2019-2026.
The global brachytherapy market is projected to be worth USD 548.8 Million by 2027, according to a current analysis by Emergen Research. The brachytherapy market is experiencing an increased demand attributed to its growing application in the treatment of cancer.
The global blood testing market is estimated to garner around USD 140 billion in revenue by the end of 2031 by growing at a CAGR of nearly 8% throughout the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to the increasing prevalence of infectious and chronic diseases, such as COVID-19, influenza, diabetes, cardiovascular diseases, liver diseases, and various cancers.
The growing number of clinical trials and the increasing adoption of immunoassay techniques are among the primary factors driving the cancer/tumor profiling market Get a PDF Sample for more detailed market insights: Visit the following link: https://www.imarcgroup.com/cancer-tumor-profiling-market E-mail: sales@imarcgroup.com Contact: +91-120-415-5099
By the end of the year 2022, China Cancer Test Market is expected to cross US$ 24 Billion. With the speedy economic development of China, incredible changes have been seen in the Chinese population because of environmental conditions, dietary intake, chronic infection, lifestyle factors and nutritional status. As a result, the cancer upshot in China has increased over the past three decades. Request a free sample copy of the report: http://www.renub.com/contactus.php 26 types of cancers were as follows: Lip, oral cavity, & pharynx (except nasopharynx), Nasopharynx, Esophagus, Stomach, Colorectum, Liver, Gallbladder, Pancreas, Larynx, Lung, Other thoracic organs, Bone, Melanoma, of the skin, Breast, Cervix, Uterus, Ovary, Prostate, Testis, Kidney, Bladder, Brain, CNS, Thyroid, Lymphoma, Leukemia and All other sites and unspecified. Get Free 10% Customization in This Report Access full Research: http://www.renub.com/china-cancer-test-market-volume-forecast-male-female-p.php
Global Cancer Biomarkers Market By Type (genetic biomarkers, protein biomarkers, other cancer biomarkers) cancer type (breast cancer, lung cancer, prostate cancer, colorectal cancer , blood cancer, melanoma , ovarian cancer, liver cancer, stomach cancer, other cancer types ), technology ( imaging technologies, omic technologies (proteomics, genomics, other omic technologies), cytogenetics-based tests, immunoassays), applications (drug discovery and development, personalized medicine, diagnostics, others)